Monte Rosa Therapeutics Inc Stock

$5.47

0.28% today

Nasdaq, Feb 28, 05:18 pm CET

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Monte Rosa Therapeutics Inc Stock price

$5.45

-15.73 74.27% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.33 5.71%

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$334.83m
Enterprise Value	$136.34m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	9.10
P/S ratio (TTM) P/S ratio	22.35
P/B ratio (TTM) P/B ratio	1.63
Revenue (TTM) Revenue	$14.98m
EBIT (operating result TTM) EBIT	$-128.98m
Free Cash Flow (TTM) Free Cash Flow	$-62.79m
Cash position	$242.19m
EPS (TTM) EPS	$-1.83
P/E forward	negative
P/S forward	5.06
EV/Sales forward	2.06
Short interest	24.01%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	15 15	- 100%
- Direct Costs	7.91 7.91	12% 12% 53%
Gross Profit	7.07 7.07	200% 200% 47%
- Selling and Administrative Expenses	26 26	5% 5% 175%
- Research and Development Expense	102 102	0% 0% 680%
EBITDA	-121 -121	10% 10% -808%
- Depreciation and Amortization	7.91 7.91	12% 12% 53%
EBIT (Operating Income) EBIT	-129 -129	8% 8% -861%
Net Profit	-119 -119	10% 10% -797%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Monte Rosa Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

4 days ago

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m.

Positive

Seeking Alpha

●

12 days ago

Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN

One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partnerships with Roche and Novartis, which I think validate its technology to some extent, but have also given it non-dilutive funding. Currently, its pipeline has MRT‑2359, MRT‑6160, and MRT‑8102, wit...

Neutral

GlobeNewsWire

●

about 2 months ago

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.

More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office	United States
CEO	Markus Warmuth
Employees	133
Founded	2019
Website	www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now